CoChat

The DOI matches its Crossref record; 161 of the 162 references it cites were found in a registry or an index.

Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer

Open access

Abstract

Radiotherapy is an important component of current treatment options for colorectal cancer (CRC). It is either applied as neoadjuvant radiotherapy to improve local disease control in rectal cancers or for the treatment of localized metastatic lesions of CRC. DNA double-strand breaks (DSBs) are the major critical lesions contributing to ionizing radiation (IR)-induced cell death. However, CRC stem cells promote radioresistance and tumor cell survival through activating cell-cycle checkpoints to trigger the DNA damage response (DDR) and DNA repair after exposure to IR. A promising strategy to overcome radioresistance is to target the DDR and DNA repair pathways with drugs that inhibit activated cell-cycle checkpoint proteins, thereby improving the sensitivity of CRC cells to radiotherapy. In this review, we focus on the preclinical studies and advances in clinical trials of DNA-dependent protein kinase catalytic subunit (DNA-PKcs), ataxia telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related kinase (ATR), checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2), WEE1 and poly (ADP-ribose) polymerase 1 (PARP1) kinase inhibitors in CRC. Importantly, we also discuss the selective radiosensitization of CRC cells provided by synthetic lethality of these inhibitors and the potential for widening the therapeutic window by targeting the DDR and DNA repair pathways in combination with radiotherapy and immunotherapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/cancers14194874

Cites

161 of 161 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram of ionizing radiation (IR)-induced DNA damage response and DNA repair. Cell-cycle checkpoints are activated in response to IR-induced DNA damage. ATM kinase is activated primarily by DNA double-strand breaks (DSBs) and mediates the initial response to DSBs as well as cell-cycle arrest through activation of CHK2. P53 activates the G1/S checkpoint via p21 to promote DNA repair or to induce apoptosis or senescence. DNA single-strand breaks (SSBs) activate ATR kinase, which in turn activates the S-phase checkpoint and G2/M checkpoint through the action of CHK1 and WEE1. The base excision repair (BER) repairs SSBs and base damage with fast kinetics. Non-homologous end-joining (NHEJ) repairs most direct 2-ended IR-induced DSBs and is the main pathway to repair DSBs in the G1 phase. Homologous recombination (HR) is essential for the repair of complicated DSBs and can only function in the presence of sister chromatids during the S and G2 phase.
Figure 1 Schematic diagram of ionizing radiation (IR)-induced DNA damage response and DNA repair. Cell-cycle checkpoints are activated in response to IR-induced DNA damage. ATM kinase is activated primarily by DNA double-strand breaks (DSBs) and mediates the initial response to DSBs as well as cell-cycle arrest through activation of CHK2. P53 activates the G1/S checkpoint via p21 to promote DNA repair or to induce apoptosis or senescence. DNA single-strand breaks (SSBs) activate ATR kinase, which in turn activates the S-phase checkpoint and G2/M checkpoint through the action of CHK1 and WEE1. The base excision repair (BER) repairs SSBs and base damage with fast kinetics. Non-homologous end-joining (NHEJ) repairs most direct 2-ended IR-induced DSBs and is the main pathway to repair DSBs in the G1 phase. Homologous recombination (HR) is essential for the repair of complicated DSBs and can only function in the presence of sister chromatids during the S and G2 phase.CC BY · PubMed Central
Figure 2 Radiotherapy (RT) causes DNA damage, and DDR inhibitors selectively mediate G2 checkpoint inhibition, allowing cells with unrepaired DNA to prematurely enter into mitosis, ultimately leading to mitotic catastrophe. DNA damage induces the release of damage-associated molecular pattern (DAMP) molecules. For example, HMGB1 is released into the extracellular environment and then mediates potent pro-inflammatory effects by binding to its downstream receptors such as Toll-like receptors (TLR) and receptors for advanced glycation end products (RAGE) to stimulate efficient processing and cross-presentation of tumor antigens from dying cells. Naive T cells differentiate into tumor-specific CD8+ T cells in response to type I interferon (IFN), leading to activation of anti-tumor immune responses and increased immunogenic cell death. On the other hand, DDR inhibition and mitotic death contribute to the formation of micronuclei, which is detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells. For the nomenclature of early cell death, regulated cell death, immunogenic cell death and mitotic catastrophe, please see the review by Galluzzi et al. [74].
Figure 2 Radiotherapy (RT) causes DNA damage, and DDR inhibitors selectively mediate G2 checkpoint inhibition, allowing cells with unrepaired DNA to prematurely enter into mitosis, ultimately leading to mitotic catastrophe. DNA damage induces the release of damage-associated molecular pattern (DAMP) molecules. For example, HMGB1 is released into the extracellular environment and then mediates potent pro-inflammatory effects by binding to its downstream receptors such as Toll-like receptors (TLR) and receptors for advanced glycation end products (RAGE) to stimulate efficient processing and cross-presentation of tumor antigens from dying cells. Naive T cells differentiate into tumor-specific CD8+ T cells in response to type I interferon (IFN), leading to activation of anti-tumor immune responses and increased immunogenic cell death. On the other hand, DDR inhibition and mitotic death contribute to the formation of micronuclei, which is detected by cyclic GMP-AMP synthase (cGAS) and stimulate production of type I IFN as well as other inflammatory cytokines via the STING pathway, thereby triggering anti-tumor immune responses by CD8+ T cells. For the nomenclature of early cell death, regulated cell death, immunogenic cell death and mitotic catastrophe, please see the review by Galluzzi et al. [74].CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 162 references

Cited by

See all 67

Metadata

Authors
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C.
Affiliations
Heidelberg University (DE)
Corresponding author
Herskind, Carsten
Venue
Cancers
Publisher
MDPI AG
Published
2022-10-05
Volume
14
Issue
19
Pages
4874
ISSN
2072-6694 (ISSN-L)
OpenAlex
W4303621977
Cited by
62
References
162
Citations by year
2026: 18 · 2025: 22 · 2024: 12 · 2023: 10
FWCI
1.17
Type
journal article
Language
en
Open access
Locations
  • Cancers (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • China Scholarship Council (202106070027, 404521405)
  • Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) (202106070027, 404521405)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
  • Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
  • Physical Sciences › Physics and Astronomy › Radiation › Radiation Therapy and Dosimetry
Keywords
colorectal cancer, radiosensitization, DNA damage response, DNA repair, radioresistance (biology), DNA double-strand breaks, cell cycle checkpoints, DNA-PKcs inhibitor, ATM inhibitors, ATR inhibitors, CHK1 inhibitor, CHK2 inhibitors, WEE1 inhibitor, PARP-1 inhibitors, synthetic lethality, combination immunotherapy, rectal cancer

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. https://app.cochat.ai/papers/10.3390/cancers14194874
The paper
Deng, S., Vlatkovic, T., Li, M., Zhan, T., Veldwijk, M. R., & Herskind, C. (2022). Targeting the DNA Damage Response and DNA Repair Pathways to Enhance Radiosensitivity in Colorectal Cancer. Cancers. https://doi.org/10.3390/cancers14194874

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.